Eventide Asset Management LLC Sells 341,635 Shares of IDEAYA Biosciences, Inc. $IDYA

Eventide Asset Management LLC lowered its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 54.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 284,069 shares of the company’s stock after selling 341,635 shares during the period. Eventide Asset Management LLC’s holdings in IDEAYA Biosciences were worth $9,820,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Farther Finance Advisors LLC increased its position in shares of IDEAYA Biosciences by 171.1% in the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after buying an additional 580 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its position in shares of IDEAYA Biosciences by 49.4% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after buying an additional 380 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new stake in shares of IDEAYA Biosciences in the 3rd quarter valued at $38,000. Global Retirement Partners LLC bought a new stake in shares of IDEAYA Biosciences in the 4th quarter valued at $61,000. Finally, Abich Financial Wealth Management LLC bought a new stake in shares of IDEAYA Biosciences in the 3rd quarter valued at $58,000. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Performance

Shares of NASDAQ IDYA opened at $28.98 on Monday. The firm has a market cap of $2.55 billion, a PE ratio of -18.11 and a beta of -0.04. IDEAYA Biosciences, Inc. has a 1-year low of $20.50 and a 1-year high of $39.28. The company has a fifty day moving average price of $29.89 and a 200 day moving average price of $32.47.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The company had revenue of $6.56 million for the quarter, compared to analysts’ expectations of $5.04 million. The company’s revenue for the quarter was down 39.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.82) earnings per share. Equities research analysts forecast that IDEAYA Biosciences, Inc. will post -4.27 EPS for the current year.

Wall Street Analyst Weigh In

IDYA has been the subject of a number of recent analyst reports. Wells Fargo & Company upped their price objective on shares of IDEAYA Biosciences from $44.00 to $48.00 and gave the company an “overweight” rating in a research report on Tuesday, April 14th. Wall Street Zen upgraded shares of IDEAYA Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday. The Goldman Sachs Group upped their price objective on shares of IDEAYA Biosciences from $31.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, April 14th. Royal Bank Of Canada upped their target price on shares of IDEAYA Biosciences from $49.00 to $53.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 14th. Finally, Guggenheim upped their target price on shares of IDEAYA Biosciences from $50.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday, April 14th. Fifteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, IDEAYA Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $50.69.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.